Q4 2025 Earnings Call March 3, 2026 4:30 PM ESTCompany ParticipantsPatrick Soon-Shiong - Founder, Executive Chairman and ...
AN2 Therapeutics, Inc. , a clinical-stage biopharmaceutical company developing novel small molecule therapeutics derived from its boron chemistry platform, today announced its plans to expand the ...
Cumberland Pharmaceuticals Inc. ( CPIX) Q4 2025 Earnings Call March 3, 2026 4:30 PM EST Good afternoon, and welcome to Cumberland Pharmaceuticals 2025 Financial Report and Company Update. This call is ...
Ifetroban Clinical Progress -- Phase II FIGHT DMD trial showed high-dose treatment improved LVEF by 3.3% versus placebo and 5.4% over propensity-matched controls, with Fast Track, Orphan Drug, and ...
Overview of secondary liver cancer care pathways, key treatment steps, and the situations where dendritic cell treatment may be discussed as a selected option.
Higher drug exposure in women due to lower renal and hepatic clearance and body composition can increase efficacy but also toxicity, highlighting the need to reassess dosing.
February 2026 coverage highlighted combination EGFR therapy guidance, chemo-free treatment options, biomarker testing and survivorship lung health.
Droplet Biosciences uses lymph fluid and NVIDIA Parabricks to detect residual cancer faster and cut analysis time and costs.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results